AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery and consumer product dispensing, dosing and protection ...
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, ...
ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its fourth quarter and full year 2025 investor update conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, ...
Acquisition of Faeth and concurrent $200 million private investment positions the combined company to advance its pipeline ...
JLL Partners (“JLL” or the “Firm”), a New York-based middle market private equity firm focused on investing in the healthcare ...
The global hospital information systems (HIS) market is projected to register a compound annual growth rate (CAGR) of ...
Round led by Heran Partners and joined by Clave Capital, Inveready and Bio&Tech Smart CapitalFinancing will enable ...
The global beauty supplements market is projected to expand at a compound annual growth rate (CAGR) of 7% during the forecast ...
GOTHENBURG, SE / ACCESS Newswire / February 18, 2026 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A)(STO:IRLAB-A)(FRA:6IRA ...
ANK-203 is a first-in-class anchored immunotherapy designed to unlock the full therapeutic potential of monoclonal antibody CD137 through localized delivery and retentionIn preclinical studies, ...
NHS Confederation responds to NHS England letter on disruption to the supply of bone cement products
Responding to NHS England’s letter to NHS leaders on disruption to the supply of bone cement products, Rory Deighton, acute and community care director speaking on behalf of NHS Providers and the NHS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results